Miso Information Technology Co., Ltd. (CEO Nam Sang-do) , a multimodal data platform specialist, announced on the 5th that it has signed a strategic business partnership (MOU) with data bio specialist Insilicogen Co., Ltd. (CEO Choi Nam-woo) to build a digital healthcare and bio data convergence ecosystem.
Through this agreement, the two companies plan to begin full-scale cooperation in various fields, including ▲fusion of medical data platforms and biodata archiving technology ▲joint development of AI-based precision medical solutions ▲cooperation in new drug development and clinical data analysis ▲technology cooperation in the agricultural and seed industries ▲joint entry into the global bio-healthcare market.
Miso Information Technology has been providing medical data integration and analysis solutions based on its technological prowess across the digital healthcare landscape, including hospital information systems (HIS), personal health records (PHRs), and clinical research as a service (CRaaS) platforms. Recently, Miso Information Technology has been recognized for its expertise in AI autonomous manufacturing, earning certification as an AI Factory Specialist, solidifying its position as an industrial and medical data integration platform provider.
Insilicogen is a company that has developed genome analysis, gene archiving, and precision diagnostic solutions based on bioinformatics. Based on its biodata processing capabilities and expertise, it is securing competitiveness in the precision medicine and omics-based analysis markets.
“This partnership will serve as an opportunity to strengthen the foundation for precision medicine, new drug development, and entry into the global healthcare market by connecting medical and bio data,” said Dong-wook Ahn, Chairman of Smile Information Technology. “We will establish a business model that can be expanded into various industries, such as agriculture, the seed industry, and One Health.”
Insilicogen CEO Nam-Woo Choi said, “We have secured competitiveness in the digital healthcare market based on our analytical capabilities utilizing genomic and omics data,” and “Through this collaboration, we will further expand our business areas into the biohealth field, including the development of an AI-based precision medicine platform.”
- See more related articles
You must be logged in to post a comment.